Table 1 Summary of trial characteristics and results
From: Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
PALOMA-2 trial | MONALEESA-2 trial | MONALEESA-7 trial | MONARCH-3 trial | |
|---|---|---|---|---|
cdk4/6inh | Palbociclib | Ribociclib | Ribociclib | Abemacicl |
Number of patients AI + placebo arm | 222 | 334 | 337 | 165 |
Median PFS AI + placebo arm | 14.5 months | 14.7 months | 13 months | 14.7 months |
Number of patients AI + cdk4/6inh arm | 444 | 334 | 337 | 328 |
Median PFS AI + cdk4/6inh arm | 24.8 months | Not reached | 23.8 months | Not reached |
PFS hazard ratio [95%CI] | 0.58 [0.46; 0.72] | 0.56 [0.43; 0.72] | 0.55a | 0.54 [0.41; 0.72] |
